Judson I - Search Results

1

Pharmacokinetic-pharmacodynamic relationships for the heat shock protein 90 molecular chaperone inhibitor 17-allylamino, 17-demethoxygeldanamycin in human ovarian cancer xenograft models.

Banerji U, Walton M, Raynaud F, Grimshaw R, Kelland L, Valenti M, Judson I, Workman P. Banerji U, et al. Among authors: judson i. Clin Cancer Res. 2005 Oct 1;11(19 Pt 1):7023-32. doi: 10.1158/1078-0432.CCR-05-0518. Clin Cancer Res. 2005. PMID: 16203796

2

Phase I trial and pharmacokinetics of trimelamol (N2,N4,N6-trihydroxymethyl-N2,N4,N6-trimethylmelamine).

Judson IR, Calvert AH, Rutty CJ, Abel G, Gumbrell LA, Graham MA, Evans BD, Wilman DE, Ashley SE, Cairnduff F. Judson IR, et al. Cancer Res. 1989 Oct 1;49(19):5475-9. Cancer Res. 1989. PMID: 2670205 Clinical Trial.

3

In vitro and in vivo antitumor activity of benzyl isothiocyanate: a natural product from Tropaeolum majus.

Pintão AM, Pais MS, Coley H, Kelland LR, Judson IR. Pintão AM, et al. Among authors: judson ir. Planta Med. 1995 Jun;61(3):233-6. doi: 10.1055/s-2006-958062. Planta Med. 1995. PMID: 7617765

4

The measurement of polyglutamate metabolites of the thymidylate synthase inhibitor, ICI D1694, in mouse and human cultured cells.

Gibson W, Bisset GM, Marsham PR, Kelland LR, Judson IR, Jackman AL. Gibson W, et al. Among authors: judson ir. Biochem Pharmacol. 1993 Feb 24;45(4):863-9. doi: 10.1016/0006-2952(93)90170-2. Biochem Pharmacol. 1993. PMID: 7680860

5

Preclinical pharmacology of 1069C85, a novel tubulin binder.

Raynaud FI, Kelland LR, Walton MI, Judson IR. Raynaud FI, et al. Among authors: judson ir. Cancer Chemother Pharmacol. 1994;35(2):169-73. doi: 10.1007/BF00686642. Cancer Chemother Pharmacol. 1994. PMID: 7987996

6

Phase I trial of ZD1694, a new folate-based thymidylate synthase inhibitor, in patients with solid tumors.

Clarke SJ, Hanwell J, de Boer M, Planting A, Verweij J, Walker M, Smith R, Jackman AL, Hughes LR, Harrap KR, Kennealey GT, Judson IR. Clarke SJ, et al. Among authors: judson ir. J Clin Oncol. 1996 May;14(5):1495-503. doi: 10.1200/JCO.1996.14.5.1495. J Clin Oncol. 1996. PMID: 8622063 Clinical Trial.

7

Pharmacokinetics of G3139, a phosphorothioate oligodeoxynucleotide antisense to bcl-2, after intravenous administration or continuous subcutaneous infusion to mice.

Raynaud FI, Orr RM, Goddard PM, Lacey HA, Lancashire H, Judson IR, Beck T, Bryan B, Cotter FE. Raynaud FI, et al. Among authors: judson ir. J Pharmacol Exp Ther. 1997 Apr;281(1):420-7. J Pharmacol Exp Ther. 1997. PMID: 9103525

8

Phase I and pharmacokinetic study of an oral platinum complex given daily for 5 days in patients with cancer.

McKeage MJ, Raynaud F, Ward J, Berry C, O'Dell D, Kelland LR, Murrer B, Santabárabara P, Harrap KR, Judson IR. McKeage MJ, et al. Among authors: judson ir. J Clin Oncol. 1997 Jul;15(7):2691-700. doi: 10.1200/JCO.1997.15.7.2691. J Clin Oncol. 1997. PMID: 9215842 Clinical Trial.

9

Mini-review: discovery and development of platinum complexes designed to circumvent cisplatin resistance.

Kelland LR, Sharp SY, O'Neill CF, Raynaud FI, Beale PJ, Judson IR. Kelland LR, et al. Among authors: judson ir. J Inorg Biochem. 1999 Oct;77(1-2):111-5. J Inorg Biochem. 1999. PMID: 10626362 Review.

10

Patterns of elevation of plasma 2'-deoxyuridine, a surrogate marker of thymidylate synthase (TS) inhibition, after administration of two different schedules of 5-fluorouracil and the specific TS inhibitors raltitrexed (Tomudex) and ZD9331.

Ford HE, Mitchell F, Cunningham D, Farrugia DC, Hill ME, Rees C, Calvert AH, Judson IR, Jackman AL. Ford HE, et al. Clin Cancer Res. 2002 Jan;8(1):103-9. Clin Cancer Res. 2002. PMID: 11801545 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

393 results

Search Page

Filters